Milatuzumab-doxorubicin conjugate: Phase I/II started

Immunomedics began an open-label, U.S. Phase I/II trial to evaluate 4 dose levels of IV milatuzumab conjugated with doxorubicin for up to 8 cycles in groups of 3-6 patients. The company plans to enro...